ReNeuron Group plc - Interim Results for the six months ended 30 Sept
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 which is part of
ReNeuron Group plc
("ReNeuron", the "Group" or the "Company")
Interim Results for the six months ended
ReNeuron Group plc (AIM: RENE), a
FINANCIAL HIGHLIGHTS
- Revenue for the period of
- Loss for the period of
- Reduced operating costs incurred in the period of
- Reduced net cash used in operating activities of
- Cash, cash equivalents and bank deposits at
OPERATIONAL HIGHLIGHTS
- During the period, the Company has been focussing on generating in vivo data to validate the CustomEXTM platform. In September we announced that the Company had successfully generated data demonstrating distinct organ and cellular targeting capabilities of its exosomes
- Today, it was announced that the Group will be presenting the data that formed the basis of that announcement, namely:
o confirmation in vitro and in vivo that exosome targeting is dependent on cell source and selection of a specific exosome population results in the improved delivery of therapeutic payloads when compared to a conventional HEK293 exosome approach;
o a specific CustomEX™ exosome targets the lymph nodes (immune system) proportionately more than other exosome types;
o a specific CustomEX™ exosome selectively targets the tubules within the kidney;
o a specific CustomEX™ exosome targets the lung following systemic administration;
o confirmation that therapeutic payloads can be successfully delivered in vivo using the CustomEX™ platform following systemic administration; and
o no evidence of immune response or toxicity with any of the exosome candidates, opening up the possible use of CustomEX™ for repeat administration unlike viral vectors.
- These data highlight the significant improvement in targeting and delivery of payloads that can be achieved through the careful selection of specific exosomes from different cell sources. ReNeuron's CustomEXTM platform, is a compelling platform that offers this ability to select the exosome cell type for a partner's need and the payload / target cell of their choice, while offering a scalable and repeatable manufacturing process due to its patented conditional immortalisation technology. This technology was enabled through the Group's earlier work in producing GMP stem cells approved by the FDA and MHRA for the clinic from which the Group's exosomes are now produced.
Enquiries:
|
ReNeuron |
||
|
|
Via Walbrook PR |
|
|
|
|
|
|
|
|
|
|
Allenby Capital Limited (Nominated Adviser and Broker) |
+44 (0)20 3328 5656 |
|
|
(Corporate Finance) |
|
|
|
|
|
|
|
|
|
|
|
Walbrook PR (Media & Investor Relations) |
+44 (0)20 7933 8780 or reneuron@walbrookpr.com |
|
|
|
+44 (0)7980 541 893 / +44 (0)7407 804 654 |
|
About ReNeuron
ReNeuron has developed a proprietary stem cell-derived, exosome-based, drug delivery platform with customisable cellular targeting capabilities for the delivery of complex drug modalities.
Through the generation of several unique and scalable exosome producer cell lines, our CustomEX™ platform can be optimised for specific tissues targets and payloads leading to improvements in therapeutic outcome and a reduction in off-target effects. ReNeuron offers a delivery mechanism for a variety of payloads such as siRNA, mRNA, proteins, small molecules and genes. Through its conditionally immortalised induced pluripotent stem cell (iPSC) platform, the Group can make allogeneic tissue cells of choice and has the potential to produce exosomes with tissue specific targeting ability.
ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. For further information visit www.reneuron.com
This announcement contains forward-looking statements with respect to the financial condition, results of operations and business achievements/performance of ReNeuron and certain of the plans and objectives of management of ReNeuron with respect thereto. These statements may generally, but not always, be identified by the use of words such as "should", "expects", "estimates", "believes" or similar expressions. This announcement also contains forward-looking statements attributed to certain third parties relating to their estimates regarding the growth of markets and demand for products. By their nature, forward-looking statements involve risk and uncertainty because they reflect ReNeuron's current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of factors could cause ReNeuron's actual financial condition, results of operations and business achievements/performance to differ materially from the estimates made or implied in such forward-looking statements and, accordingly, reliance should not be placed on such statements.
INTERIM RESULTS FOR THE SIX MONTHS ENDED
EXECUTIVE CHAIRMAN'S STATEMENT
In a very uncertain world, the financial markets remain extremely volatile. Specifically, in the biotech sector many companies have found themselves coming under increasing financial pressure and as a result we have seen a number of biotech company liquidations. ReNeuron faces similar challenges in the current financial climate but the Board remains positive regarding the future viability of the business.
The Group ended the period to
Nine months ago, we set out to generate critical in vivo data to support our CustomEX™ exosome delivery platform and from an R&D perspective it has been a very successful period as evidenced by the data being presented today at the Cell 2023 conference in
I believe that in CustomEX™ we are on our way to developing a leading-edge platform for the targeted delivery of modern-day therapies and, provided we continue to have our shareholders support, we can deliver on the promise of creating a highly valuable delivery platform and, consequently, a highly valued business entity.
I would like to thank our team in Pencoed supported by our third-party collaborators and advisers as we remain committed to progressing the development of this platform, establishing meaningful partnerships and funding the business appropriately.
Outlook
The outlook for ReNeuron remains positive provided we can retain our highly dedicated team of scientists and further develop and verify the CustomEX™ exosome delivery platform and conclude validating industry partnerships. We aim to do this by a variety of means including potentially raising more equity financing and/or securing a financing facility and/or entering into M&A discussions; none of which have been ruled out at the time of writing.
Executive Chairman
FINANCIAL REVIEW
Following the restructure in
At
Details on the Directors' assessment on going concern is provided in note 3 to the interim financial statements.
|
FINANCIAL HIGHLIGHTS (£'000) |
Six months ended |
Six months ended |
Year ended |
|
Cash, cash equivalents & bank deposits |
5,075 |
10,464 |
7,153 |
|
Net cash used in operating activities |
2,101 |
4,323 |
7,484 |
|
Revenue |
157 |
438 |
530 |
|
Operating expenses |
3,457 |
4,712 |
7,645 |
|
Finance income |
91 |
466 |
478 |
|
Total comprehensive loss |
2,841 |
3,176 |
5,408 |
Revenue and Other Operating Income
In the six months to
Operating expenses
Total operating expenses reduced in the period to
This reduction in costs followed the restructuring in
Finance income/expense
Finance income represented income received from the Group's cash and investments and gains from foreign exchange, with losses from foreign exchange shown in finance expense.
Finance income was
The Group holds cash and investments in foreign currencies to hedge against operational spend in those currencies. The strengthening of sterling during the period resulted in a decrease in valuation of the Group's foreign currency balances.
Taxation
The taxation credit for the period of
Cash flow
Net cash used in operating activities in the period reduced to
The Group had cash, cash equivalents and bank deposits totalling
Statement of financial position
The Company invested in property, plant and equipment in the prior year and no capital investment was required in the six months to
Current assets include a corporation tax receivable of
Current liabilities primarily comprise trade and other payables at
Non-current liabilities represented the lease liability relating to the Company's premises. The lease liability reduced by
Chief Financial Officer
INTERIM FINANCIAL STATEMENTS
Unaudited Consolidated Statement of Comprehensive Income
for the six months ended
|
|
|
Six months ended |
Six months ended |
Year ended |
|
|
|
30 September |
30 September |
31 March |
|
|
|
2023 |
2022 |
2023 |
|
|
Note |
£'000 |
£'000 |
£'000 |
|
Revenue |
4 |
157 |
438 |
530 |
|
Research and development costs |
|
(2,177) |
(2,986) |
(4,463) |
|
General and administrative costs |
|
(1,280) |
(1,726) |
(3,182) |
|
Operating loss |
|
(3,300) |
(4,274) |
(7,115) |
|
Finance income |
6 |
91 |
466 |
478 |
|
Finance expense |
7 |
(19) |
(10) |
(20) |
|
Loss before income taxes |
|
(3,228) |
(3,818) |
(6,657) |
|
Taxation |
8 |
387 |
642 |
1,249 |
|
Loss and total comprehensive loss for the period |
|
(2,841) |
(3,176) |
(5,408) |
|
Loss and total comprehensive loss attributable to equity owners of the company |
|
(2,841) |
(3,176) |
(5,408) |
|
|
|
|
|
|
|
Basic and diluted loss per ordinary share |
9 |
(5.0p) |
(5.6p) |
(9.5p) |
Unaudited Consolidated Statement of Financial Position
as at
|
|
|
30 September |
30 September |
31 March |
|
|
|
2023 |
2022 |
2023 |
|
|
Note |
£'000 |
£'000 |
£'000 |
|
Assets |
|
|
|
|
|
Non-current assets |
|
|
|
|
|
Property, plant and equipment |
|
258 |
354 |
338 |
|
Right-of-use asset |
10 |
234 |
331 |
283 |
|
Intangible assets |
|
186 |
186 |
186 |
|
|
|
678 |
871 |
807 |
|
Current assets |
|
|
|
|
|
Trade and other receivables |
|
317 |
456 |
500 |
|
Corporation tax receivable |
|
353 |
2,036 |
1,185 |
|
Investments - bank deposits |
|
- |
1,000 |
1,000 |
|
Cash and cash equivalents |
|
5,075 |
9,464 |
6,153 |
|
|
|
5,745 |
12,956 |
8,838 |
|
Total assets |
|
6,423 |
13.827 |
9,645 |
|
|
|
|
|
|
|
Equity |
|
|
|
|
|
Equity attributable to owners of the company |
|
|
|
|
|
Share capital |
11 |
572 |
571 |
572 |
|
Share premium account |
11 |
113,925 |
113,925 |
113,925 |
|
Capital redemption reserve |
|
40,294 |
40,294 |
40,294 |
|
Merger reserve |
|
2,223 |
2,223 |
2,223 |
|
Accumulated losses |
|
(154,593) |
(149,931) |
(151,957) |
|
Total equity |
|
2,421 |
7,082 |
5,057 |
|
Liabilities |
|
|
|
|
|
Current Liabilities |
|
|
|
|
|
Trade and other payables |
|
3,657 |
6,249 |
4,167 |
|
Lease liabilities |
|
156 |
151 |
153 |
|
|
|
3,813 |
6,400 |
4,320 |
|
Non-current liabilities |
|
|
|
|
|
Lease liabilities |
|
189 |
345 |
268 |
|
|
|
189 |
345 |
268 |
|
Total liabilities |
|
4,002 |
6,745 |
4,588 |
|
Total equity and liabilities |
|
6,423 |
13,827 |
9,645 |
Unaudited Consolidated Statement of Changes in Equity
for the six months ended
|
|
|
Share |
Capital |
|
|
|
|
|
Share |
premium |
redemption |
Merger |
Accumulated |
Total |
|
|
capital |
account |
reserve |
reserve |
losses |
Equity |
|
|
£'000 |
£'000 |
£'000 |
£'000 |
£'000 |
£'000 |
|
As at |
571 |
113,925 |
40,294 |
2,223 |
(147,125) |
9,888 |
|
Credit on share-based payment |
- |
- |
- |
- |
370 |
370 |
|
Loss and total comprehensive loss for the period |
- |
- |
- |
- |
(3,176) |
(3,176) |
|
As at |
571 |
113,925 |
40,294 |
2,223 |
(149,931) |
7,082 |
|
Exercise of employee share options |
1 |
- |
- |
- |
- |
1 |
|
Credit on share-based payment |
- |
- |
- |
- |
206 |
206 |
|
Loss and total comprehensive loss for the period |
- |
- |
- |
- |
(2,232) |
(2,232) |
|
As at |
572 |
113,925 |
40,294 |
2,223 |
(151,957) |
5,057 |
|
Credit on share-based payment |
- |
- |
- |
- |
205 |
205 |
|
Loss and total comprehensive loss for the period |
- |
- |
- |
- |
(2,841) |
(2,841) |
|
As at |
572 |
113,925 |
40,294 |
2,223 |
(154,593) |
2,421 |
Unaudited Consolidated Statement of Cash Flows
for the six months ended
|
|
|
Six months ended |
Six months ended |
Year ended |
|
|
|
30 September |
30 September |
31 March |
|
|
|
2023 |
2022 |
2023 |
|
|
Note |
£'000 |
£'000 |
£'000 |
|
Cash flows from operating activities |
|
|
|
|
|
Cash used in operations |
12 |
(3,312) |
(4,310) |
(8,920) |
|
Overseas taxes paid |
|
(16) |
(3) |
(5) |
|
Income tax credit received |
|
1,235 |
- |
1,461 |
|
Interest paid |
|
(8) |
(10) |
(20) |
|
Net cash used in operating activities |
|
(2,101) |
(4,323) |
(7,484) |
|
|
|
|
|
|
|
Cash flows from investing activities |
|
|
|
|
|
Capital expenditure |
|
- |
(156) |
(220) |
|
Bank deposit matured |
|
1,000 |
4,000 |
4,000 |
|
Interest received |
|
110 |
32 |
131 |
|
Net cash generated by investing activities |
|
1,110 |
3,876 |
3,911 |
|
|
|
|
|
|
|
Cash flows from financing activities |
|
|
|
|
|
Proceeds from the issue of ordinary shares |
|
- |
- |
1 |
|
Principal element of lease payments |
|
(76) |
(66) |
(148) |
|
Net cash used in financing activities |
|
(76) |
(66) |
(147) |
|
|
|
|
|
|
|
Net decrease in cash and cash equivalents |
13 |
(1,067) |
(513) |
(3,720) |
|
Effect of foreign exchange rates |
|
(11) |
429 |
325 |
|
Cash and cash equivalents at the start of period |
|
6,153 |
9,548 |
9,548 |
|
Cash and cash equivalents at the end of period |
14 |
5,075 |
9,464 |
6,153 |
Notes to the Interim Financial Statements
for the six months ended
1. General information and basis of preparation
ReNeuron Group plc is an AIM listed company incorporated and domiciled in the
These Interim Financial Statements were prepared by the Directors and approved for issue on
These Interim Financial Statements do not comprise statutory accounts within the meaning of section 434 of the Companies Act 2006. Statutory accounts for the year ended
As permitted, these Interim Financial Statements have been prepared in accordance with
2. Accounting policies
The accounting policies applied are consistent with those of the Annual Financial Statements for the year ended
3. Going concern
The operations of the Group are currently being financed from funds that have been raised from share placings, commercial partnerships and grants.
The goal of the Group is to achieve the commercial validation of the CustomExTM platform by generating in vivo data aimed at differentiating the platform from that of its competitors. As previously reported, the Group has been successful in generating such data and the group is now further broadening its capabilities with a focus on the functional delivery of specific payloads.
The Directors continue to seek opportunities to secure further revenues/funding sufficient for the short to medium term future needs of the business and the current favourable in vivo data should enhance those opportunities. Considerable emphasis is placed on communication with shareholders, potential investors and other commercial organisations in order to maximise the chances of success in exploiting these opportunities.
In
Based on the internal forecasts prepared and various options being explored and considered by the Board, the Directors consider it appropriate to continue to adopt the going concern basis in the preparation of these interim results. However, there is no guarantee that attempts to secure adequate cash inflows from the Group's exosome platform and IP or through equity fund raising within the timescales stated above will be successful. These conditions indicate the existence of a material uncertainty, which may cast significant doubt about the Group's ability to continue as a going concern. These unaudited interim financial statements do not include the adjustments that would result if the Group and Company were unable to continue as a going concern.
4. Revenue
|
|
Six months |
Six months |
|
|
|
Ended |
Ended |
Year ended |
|
|
30 September |
30 September |
31 March |
|
|
2023 |
2022 |
2023 |
|
|
£'000 |
£'000 |
£'000 |
|
Royalty income |
51 |
45 |
136 |
|
Income associated with development activities |
106 |
393 |
394 |
|
|
157 |
438 |
530 |
Royalty income is derived from the licensed sale of the Group's products to customers in the
Income associated with development activities relates to fees received under research agreements and is generated in the
5. Segment information
The Group has identified the Executive Chairman as the Chief Operating Decision Maker (CODM). The CODM manages the business as one segment, the development of stem cell derived exosome technologies. Since this is the only reporting segment, no further information is included. The information used internally by the CODM is the same as that disclosed in the Interim Financial Statements. Revenue is analysed in note 4 above.
6. Finance income
|
|
Six months |
Six months |
|
|
|
Ended |
Ended |
Year ended |
|
|
30 September |
30 September |
31 March |
|
|
2023 |
2022 |
2023 |
|
|
£'000 |
£'000 |
£'000 |
|
Interest received |
91 |
37 |
153 |
|
Foreign exchange gains |
- |
429 |
325 |
|
|
91 |
466 |
478 |
7. Finance expense
|
|
Six months |
Six months |
|
|
|
|
Ended |
Ended |
Year ended |
|
|
|
30 September |
30 September |
31 March |
|
|
|
2023 |
2022 |
2023 |
|
|
|
£'000 |
£'000 |
£'000 |
|
|
Lease interest |
8 |
10 |
20 |
|
|
Foreign exchange losses |
11 |
- |
- |
|
|
|
19 |
10 |
20 |
|
8. Taxation
|
|
Six months |
Six months |
|
|
|
Ended |
Ended |
Year ended |
|
|
30 September |
30 September |
31 March |
|
|
2023 |
2022 |
2023 |
|
|
£'000 |
£'000 |
£'000 |
|
R & D tax credit |
353 |
644 |
1,185 |
|
Overseas taxation |
(16) |
(2) |
(5) |
|
Adjustments in respect of prior years |
50 |
- |
69 |
|
|
387 |
642 |
1,249 |
9. Basic and diluted loss per share
The basic and diluted loss per share is calculated by dividing the loss for the financial period of
10. Right-of-use-asset
|
|
30 September |
30 September |
31 March |
|
|
2023 |
2022 |
2023 |
|
|
£'000 |
£'000 |
£'000 |
|
At beginning of the period |
283 |
373 |
373 |
|
Additions |
- |
7 |
7 |
|
Depreciation charge |
(49) |
(49) |
(97) |
|
At end of the period |
234 |
331 |
283 |
The net book value of the underlying assets is as follows:
|
|
30 September |
30 September |
31 March |
|
|
2023 |
2022 |
2023 |
|
|
£'000 |
£'000 |
£'000 |
|
Land and buildings |
230 |
325 |
278 |
|
Computer and office equipment |
4 |
6 |
5 |
|
At end of the period |
234 |
331 |
283 |
11. Share capital and share premium
|
|
Number of shares |
Share capital |
Share premium |
Total |
|
|
|
£'000 |
£'000 |
£'000 |
|
As at |
57,063,623 |
571 |
113,925 |
114,496 |
|
Issue of new shares - share options exercised |
82,270 |
1 |
- |
1 |
|
As at |
57,145,893 |
572 |
113,925 |
114,497 |
|
Issue of new shares - share options exercised |
27,867 |
- |
- |
- |
|
As at |
57,145,893 |
572 |
113,925 |
114,497 |
12. Cash used in operations
|
|
Six months |
Six months |
|
|
|
Ended |
Ended |
Year ended |
|
|
30 September |
30 September |
31 March |
|
|
2023 |
2022 |
2023 |
|
|
£'000 |
£'000 |
£'000 |
|
Loss before income tax |
(3,228) |
(3,818) |
(6,657) |
|
Adjustment for: |
|
|
|
|
Finance income |
(91) |
(466) |
(478) |
|
Finance expense |
19 |
10 |
20 |
|
Depreciation of property, plant and equipment |
80 |
83 |
170 |
|
Depreciation of right-of-use asset |
49 |
49 |
97 |
|
Share-based payment charges |
205 |
370 |
576 |
|
Changes in working capital: |
|
|
|
|
Receivables |
163 |
87 |
58 |
|
Payables |
(509) |
(625) |
(2,706) |
|
Cash used in operations |
(3,312) |
(4,310) |
(8,920) |
13. Reconciliation of net cash flow to movement in net debt
|
|
Six months |
Six months |
|
|
|
Ended |
Ended |
Year ended |
|
|
30 September |
30 September |
31 March |
|
|
2023 |
2022 |
2023 |
|
|
£'000 |
£'000 |
£'000 |
|
Decrease in cash and cash equivalents |
(1,067) |
(513) |
(3,720) |
|
Effect of foreign exchange rates |
(11) |
429 |
325 |
|
Cash inflow from increase in lease liabilities |
- |
(7) |
(7) |
|
Lease repayments |
84 |
83 |
168 |
|
Lease interest |
(8) |
(10) |
(20) |
|
Net funds at start of period |
5,732 |
8,986 |
8,986 |
|
Net funds at end of period |
4,730 |
8,968 |
5,732 |
14. Analysis of net funds
|
|
Six months |
Six months |
|
|
|
Ended |
Ended |
Year ended |
|
|
30 September |
30 September |
31 March |
|
|
2023 |
2022 |
2023 |
|
|
£'000 |
£'000 |
£'000 |
|
Cash and cash equivalents |
5,075 |
9,464 |
6,153 |
|
Lease liabilities |
(345) |
(496) |
(421) |
|
Net funds |
4,730 |
8,968 |
5,732 |
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.
Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.
This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.
In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.
The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
FOR OUR FULL DISCLAIMER CLICK HERE